FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280492346> ?p ?o ?g. }

• W4280492346 abstract "Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary breast cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline biopsy and residual disease (RD) in patients undergoing neoadjuvant treatment did not include the HER2-low-positive category. The aim of this study is to track the evolution of HER2-low-positive expression from primary BC to RD after neoadjuvant treatment. Patients undergoing neoadjuvant treatment with available baseline tumor tissue and matched samples of RD (in case of no pCR) were included. HER2-negative cases were sub-classified as HER2-0 or HER2-low-positive (IHC 1+ or 2+ and ISH negative). Four-hundred forty-six patients were included. Primary BC phenotype was: HR-positive/HER2-negative 23.5%, triple-negative (TN) 35%, HER2-positive 41.5%. HER2-low-positive cases were 55.6% of the HER2-negative cohort and were significantly enriched in the HR-positive/HER2-negative vs. TN subgroup (68.6% vs. 46.8%, p = 0.001 χ2 test). In all, 35.3% of non-pCR patients (n = 291) had a HER2-low-positive expression on RD. The overall rate of HER2 expression discordance was 26.4%, mostly driven by HER2-negative cases converting either from (14.8%) or to (8.9%) HER2-low-positive phenotype. Among HR-positive/HER2-negative patients with HER2-low-positive expression on RD, 32.0% and 57.1% had an estimated high risk of relapse according to the residual proliferative cancer burden and CPS-EG score, respectively. In conclusion, HER2-low-positive expression showed high instability from primary BC to RD after neoadjuvant treatment. HER2-low-positive expression on RD may guide personalized adjuvant treatment for high-risk patients in the context of clinical trials with novel anti-HER2 antibody-drug conjugates." @default.
• W4280492346 created "2022-05-22" @default.
• W4280492346 creator A5001331585 @default.
• W4280492346 creator A5013497028 @default.
• W4280492346 creator A5020747800 @default.
• W4280492346 creator A5024264121 @default.
• W4280492346 creator A5034632931 @default.
• W4280492346 creator A5046242778 @default.
• W4280492346 creator A5046301295 @default.
• W4280492346 creator A5055333835 @default.
• W4280492346 creator A5064741160 @default.
• W4280492346 creator A5068486162 @default.
• W4280492346 creator A5074094118 @default.
• W4280492346 creator A5075407319 @default.
• W4280492346 creator A5081552375 @default.
• W4280492346 creator A5085165482 @default.
• W4280492346 creator A5089001282 @default.
• W4280492346 date "2022-05-20" @default.
• W4280492346 modified "2023-10-14" @default.
• W4280492346 title "HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment" @default.
• W4280492346 cites W1813571362 @default.
• W4280492346 cites W1982992455 @default.
• W4280492346 cites W1991834223 @default.
• W4280492346 cites W2039647640 @default.
• W4280492346 cites W2044702943 @default.
• W4280492346 cites W2075894019 @default.
• W4280492346 cites W2090229207 @default.
• W4280492346 cites W2096285466 @default.
• W4280492346 cites W2098942227 @default.
• W4280492346 cites W2111717465 @default.
• W4280492346 cites W2116522870 @default.
• W4280492346 cites W2131964282 @default.
• W4280492346 cites W2136817628 @default.
• W4280492346 cites W2140927379 @default.
• W4280492346 cites W2148427383 @default.
• W4280492346 cites W2156878255 @default.
• W4280492346 cites W2157938035 @default.
• W4280492346 cites W2158040518 @default.
• W4280492346 cites W2202567942 @default.
• W4280492346 cites W2259270597 @default.
• W4280492346 cites W2531142031 @default.
• W4280492346 cites W2538484238 @default.
• W4280492346 cites W2759663528 @default.
• W4280492346 cites W2809293192 @default.
• W4280492346 cites W2902218997 @default.
• W4280492346 cites W2913236879 @default.
• W4280492346 cites W2953684910 @default.
• W4280492346 cites W2981011436 @default.
• W4280492346 cites W2991100602 @default.
• W4280492346 cites W3005585857 @default.
• W4280492346 cites W3018222852 @default.
• W4280492346 cites W3031646075 @default.
• W4280492346 cites W3032521952 @default.
• W4280492346 cites W3039622435 @default.
• W4280492346 cites W3111523327 @default.
• W4280492346 cites W3119128530 @default.
• W4280492346 cites W3134129955 @default.
• W4280492346 cites W3139109547 @default.
• W4280492346 cites W3160480119 @default.
• W4280492346 cites W3166066183 @default.
• W4280492346 cites W3179156059 @default.
• W4280492346 cites W3179495039 @default.
• W4280492346 cites W3181413846 @default.
• W4280492346 cites W3187883378 @default.
• W4280492346 cites W3202142084 @default.
• W4280492346 cites W3205002341 @default.
• W4280492346 cites W4233508824 @default.
• W4280492346 cites W7023456 @default.
• W4280492346 doi "https://doi.org/10.1038/s41523-022-00434-w" @default.
• W4280492346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35595761" @default.
• W4280492346 hasPublicationYear "2022" @default.
• W4280492346 type Work @default.
• W4280492346 citedByCount "37" @default.
• W4280492346 countsByYear W42804923462022 @default.
• W4280492346 countsByYear W42804923462023 @default.
• W4280492346 crossrefType "journal-article" @default.
• W4280492346 hasAuthorship W4280492346A5001331585 @default.
• W4280492346 hasAuthorship W4280492346A5013497028 @default.
• W4280492346 hasAuthorship W4280492346A5020747800 @default.
• W4280492346 hasAuthorship W4280492346A5024264121 @default.
• W4280492346 hasAuthorship W4280492346A5034632931 @default.
• W4280492346 hasAuthorship W4280492346A5046242778 @default.
• W4280492346 hasAuthorship W4280492346A5046301295 @default.
• W4280492346 hasAuthorship W4280492346A5055333835 @default.
• W4280492346 hasAuthorship W4280492346A5064741160 @default.
• W4280492346 hasAuthorship W4280492346A5068486162 @default.
• W4280492346 hasAuthorship W4280492346A5074094118 @default.
• W4280492346 hasAuthorship W4280492346A5075407319 @default.
• W4280492346 hasAuthorship W4280492346A5081552375 @default.
• W4280492346 hasAuthorship W4280492346A5085165482 @default.
• W4280492346 hasAuthorship W4280492346A5089001282 @default.
• W4280492346 hasBestOaLocation W42804923461 @default.
• W4280492346 hasConcept C121608353 @default.
• W4280492346 hasConcept C126322002 @default.
• W4280492346 hasConcept C142724271 @default.
• W4280492346 hasConcept C143998085 @default.
• W4280492346 hasConcept C204232928 @default.
• W4280492346 hasConcept C2775930923 @default.
• W4280492346 hasConcept C2779786085 @default.
• W4280492346 hasConcept C2910363380 @default.

• next